SPY759.09+0.26%QQQ690.87+0.39%BTC/USD70,802.20−0.80%DIA523.26+0.15%GLD355.80+0.26%TLT79.58−0.18%

MiNK Therapeutics Inc

INKTNASDAQ

Trade with Public

$9.53

-0.69-6.79%

Last update: Nov 11, 6:03 PM

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Earnings: Q3 2026 Earnings were released on Wed Nov 11th, before the market open

Conference Call: The most recent conference call started at 8:30 AM, 1 day ago

Click to view the webcast

MiNK Therapeutics (INKT) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for MiNK Therapeutics (INKT) stock.

Analyst Consensus — 4 Analysts

3Buy

1Hold

# Analysts4

Latest Upgrades and Downgrades for MiNK Therapeutics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	HC Wainwright & Co.	Matthew Keller	Assumes	Buy	$38
—	B. Riley Securities	Mayank Mamtani	PT Raise	Buy	$43→$50
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
—	HC Wainwright & Co.	Emily Bodnar	Upgrade	Neutral→Buy	$35
—	HC Wainwright & Co.	Emily Bodnar	Downgrade	Buy→Neutral	$35
—	William Blair	Matt Phipps	Downgrade	Outperform→Market Perform	—
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$35
—	HC Wainwright & Co.	Emily Bodnar	PT Raise	Buy	$9→$35
—	Baird	Jack Allen	PT Cut	Outperform	$80→$40
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
—	HC Wainwright & Co.	Emily Bodnar	Maintained	Buy	$90
—	HC Wainwright & Co.	Emily Bodnar	PT Cut	Buy	$100→$90

MiNK Therapeutics Inc

MiNK Therapeutics (INKT) Stock Price Target 2026

Latest Upgrades and Downgrades for MiNK Therapeutics Stock

MiNK Therapeutics (INKT) Stock Price Target 2026

Latest Upgrades and Downgrades for MiNK Therapeutics Stock

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

People Also Watch

People Also Watch

Analyst Ratings News

PRO
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

MiNK Therapeutics Inc

MiNK Therapeutics (INKT) Stock Price Target 2026

Latest Upgrades and Downgrades for MiNK Therapeutics Stock

MiNK Therapeutics (INKT) Stock Price Target 2026

Latest Upgrades and Downgrades for MiNK Therapeutics Stock

Analyst Ratings News

PROHC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PROB. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PROHC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

People Also Watch

People Also Watch

Analyst Ratings News

PROHC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PROB. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PROHC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PROHC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35

PRO
HC Wainwright & Co. Assumes MiNK Therapeutics at Buy, Announces Price Target of $38

PRO
B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

PRO
HC Wainwright & Co. Upgrades MiNK Therapeutics to Buy, Maintains Price Target to $35

PRO
HC Wainwright & Co. Downgrades MiNK Therapeutics to Neutral, Maintains Price Target to $35